Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
A Look at GLP-1 Results According to researchers at Shenandoah University, the medication produced clinically significant weight loss during trials conducted as part of the Semaglutide Treatment Effect in People with Obesity (STEP) program
Consider Currently Available Medications Two effective weight loss drugs are available by prescription right now
Early trial results have been promising, fueling significant interest among both patients and healthcare providers
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for several indications: type 2 diabetes mellitus, chronic weight management, and more recently, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity
US$ 20.68
US$ 25.89
US$ 29.89
US$ 20.82
US$ 26.96
US$ 24.59
US$ 28.66
US$ 27.31
US$ 28.87
US$ 25.25
US$ 23.95
